Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 Mar;158(3):997-1004.
doi: 10.1016/S0002-9440(10)64046-1.

PG490-88, a derivative of triptolide, blocks bleomycin-induced lung fibrosis

Affiliations

PG490-88, a derivative of triptolide, blocks bleomycin-induced lung fibrosis

G Krishna et al. Am J Pathol. 2001 Mar.

Abstract

In this study we evaluate the antifibrotic properties of PG-490-88, a water-soluble derivative of triptolide. Triptolide is an oxygenated diterpene that is derived from a traditional Chinese herb that has potent immunosuppressive and antitumor activity. We used the intratracheal bleomycin mouse model and found that PG490-88 inhibits fibrosis in the bleomycin group when given the same day or 5 days after bleomycin. PG490-88 also markedly reduced the number of myofibroblasts in the bleomycin treatment group. An enzyme-linked immunosorbent assay of transforming growth factor (TGF)-beta in the bronchoalveolar lavage fluid showed a significant decrease in TGF-beta in the PG490-88-treated groups compared to the bleomycin-treated group. Additionally, triptolide blocked bleomycin-induced increase in TGF-beta mRNA in cultured normal human lung fibroblasts. The efficacy of PG490-88 when administered late after bleomycin installation suggests a potential role in the treatment of idiopathic pulmonary fibrosis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
A: H&E stain: ×100. a: Saline control, normal lung architecture. b: Saline plus PG490-88, normal lung architecture. c: Bleomycin alone, extensive inflammation and fibrosis. d: Bleomycin plus PG490-88 (same day), patchy areas of inflammation with minimal fibrosis. e: Bleomycin plus PG490-88 (5 days later), patchy areas of inflammation with minimal fibrosis. B: Comparable sections of mouse lung to Figure 1 ▶ stained with trichrome: saline control: normal lung architecture (a); saline plus PG490-88, normal lung architecture (b); bleomycin alone, extensive areas of collagen (stained blue) (c); bleomycin plus PG490-88 (same day), minimal collagen (d); bleomycin plus PG490-88 (5 days later), minimal collagen (e).
Figure 2.
Figure 2.
Alpha smooth-muscle actin stain of mouse lung sections (original magnification, ×100) that detects myofibroblasts (blue arrow) and airway smooth muscle cells that are a positive control (yellow arrow). Left: Bleomycin alone, extensive accumulation of α-smooth muscle actin-positive myofibroblasts. Center: Bleomycin plus PG490-88 (same day), small number of myofibroblasts. Right: Bleomycin plus PG490-88 (5 days later), scattered areas of myofibroblasts. Consecutive sections of mouse lung tissue stained with H&E are shown for comparison.
Figure 3.
Figure 3.
Total hydroxyproline content ± SE in μg/lung. In the bleomycin plus PG490-88 (5 days) group, PG490-88 was administered 5 days after bleomycin. Four independent experiments were used for the statistical analysis that is outlined in Materials and Methods. *, P < 0.01 compared to bleomycin alone.
Figure 4.
Figure 4.
BALF levels of active TGF-β (pg/ml) ± SE measured by ELISA. *, P < 0.01 compared to bleomycin alone.
Figure 5.
Figure 5.
A: RT-PCR of TGF-β mRNA in NHLFs stimulated for 24 hours with 0.1 μg/ml or 10 μg/ml of bleomycin in the presence or absence of PG490 (20 ng/ml). GAPDH is used as a loading control. B: The ratio of TGF-β/GAPDH mRNA is shown.
Figure 6.
Figure 6.
Molecular structure of PG-490-88 and triptolide. PG490-88 is a succinate salt-water soluble derivative of triptolide that is converted to triptolide in the serum.

Similar articles

Cited by

References

    1. Katzenstein AA, Myers JL: Idiopathic pulmonary fibrosis. Clinical relevance of pathologic classification. AJRCCM 1998, 157:1301-1315 - PubMed
    1. Idiopathic pulmonary fibrosis: diagnosis and treatment: international consensus statement. AJRCCM 2000, 161:646–664 - PubMed
    1. Mapel DW, Samet JM, Coultas DB: Corticosteroids and the treatment of idiopathic pulmonary fibrosis: past, present and future. Chest 1996, 110:1058-1067 - PubMed
    1. Douglas WW, Ryu JH, Bjoraker JA, Schroder DR, Myers JL, Tazelaar HD, Swensen SJ, Peters SG, deRemee RA: Colchicine versus prednisone as treatment of usual interstitial pneumonia. Mayo Clin Proc 1997, 72:201-209 - PubMed
    1. Raghu G, Depaso WJ, Cain K, Hammar SP, Wetzel CE, Dreis DF, Hutchinson J, Pardee NE, Winterbauer RH: Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective, double blind, randomized, placebo controlled trial. Am Rev Respir Dis 1991, 144:291-296 - PubMed

Publication types

MeSH terms